TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has issued an announcement.
Chimeric Therapeutics Ltd. has announced the issuance of new unquoted equity securities, including 387,577,500 options expiring in March 2026 and 25,000,000 options expiring in October 2028. This move is part of a previously announced transaction, reflecting the company’s strategic efforts to bolster its financial position and support its ongoing research and development initiatives.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Ltd. operates in the biotechnology industry, focusing on the development of cell therapies for cancer treatment. The company is engaged in advancing innovative therapies that harness the immune system to target and destroy cancer cells.
Technical Sentiment Signal: Sell
Current Market Cap: A$13.02M
For an in-depth examination of CHM stock, go to TipRanks’ Overview page.